Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity

References

• Koller KM, Wang W, Schell TD, et al. Malignant melanoma – the cradle of anti-neoplastic immunotherapy. Crit Rev Oncol Hematol. 2016;106:25–54.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116.
   PubMed Web of Science ®Google Scholar
• Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC Med. 2016;14:20.
   PubMed Web of Science ®Google Scholar
• Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther. 2016;16:389–396.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy. 2011;8:43–54.
   PubMedGoogle Scholar
• Herzberg B, Campo MJ, Gainor JF. Immune checkpoint inhibitors in non-small cell lung cancer. Oncologist. 2017;22:81–88.
   Google Scholar
• Aranda F, Vacchelli E, Eggermont A, et al. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3:e27297.
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010;37:499–507.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34:556–563.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–212.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Yongshu L, Fangfei L, Feng J, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17:1151.
   Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–477.
   PubMed Web of Science ®Google Scholar
• Chakravarti N, Prieto VG. Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res. 2015;4:743–751.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol. 2015;42:S11–S18.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–e551.
   PubMed Web of Science ®Google Scholar
• Braun DA, Burke KP, van Allen EM. Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res. 2016;22:5642–5650.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4:560–575.
   PubMed Web of Science ®Google Scholar
• Nawaz K, Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov. 2016;15:229–230.
   PubMed Web of Science ®Google Scholar
• Webster RM. The immune checkpoint inhibitors: where are we now? Nat Drug Discov. 2014;13:883–884.
   PubMed Web of Science ®Google Scholar
• Aguiar PN Jr, De Mello R, Tadokoro H, et al. Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. Annals Oncol. 2016;27S6:abstract 1224.
   Google Scholar
• Webster RM The immuno-oncology market, key players, leading contenders and the next generation. DCAT Week, 2016 [cited 2016 Nov 17]. Available from: https://www.dcat.org/Public/Pdfs/DCATWeek16/PIO/Rachel%20Webster%20FINAL%203.11.160-OK-Distrib.pdf;
   Google Scholar
• Lu J, Lee-Gabel L, Nadeau MC, et al. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. 2015;21:451–467.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with previously treated advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31:suppl; abstr 8030.
   Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497–1508.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   PubMed Web of Science ®Google Scholar
• Bracarda S, Altavilla A, Hamzaj A, et al. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol. 2015;42:495–505.
   PubMed Web of Science ®Google Scholar
• Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30:251–260.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;31:abstr 8008.
   Web of Science ®Google Scholar
• Soria JC, Cruz C, Balheda R, et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). European Cancer Congress (ECCO-ESMO-ESTRO). Amsterdam, Netherland, 2013.
   Google Scholar
• Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016;8:593–603.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Li Y, Li F, et al. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol. 2015;38:422–430.
   PubMed Web of Science ®Google Scholar
• Yang X, Ambrogelly A. Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies. Curr Opin Biotechnol. 2014;30:225–229.
   PubMed Web of Science ®Google Scholar
• Liu K, Tan S, Chai Y, et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2017;27:151–153.
   Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148–1157.
   PubMed Web of Science ®Google Scholar
• Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42:474–483.
   PubMed Web of Science ®Google Scholar
• Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119–3125.
   PubMed Web of Science ®Google Scholar
• Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol. 2013;4:481.
   PubMed Web of Science ®Google Scholar
• Battella S, Cox MC, Santoni A, et al. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J Leukoc Biol. 2016;99:87–96.
   PubMed Web of Science ®Google Scholar
• Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123.
   PubMedGoogle Scholar
• Dahlberg CI, Sarhan D, Chrobok M, et al. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol. 2015;6:605.
   PubMed Web of Science ®Google Scholar
• Rajasekaran N, Chester C, Yonezawa A, et al. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther. 2015;4:91—100.
   PubMedGoogle Scholar
• Grenga I, Donahue RN, Lepone LM, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunol. 2016;5:e83.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Rouce RH. The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol. 2015;6:578.
   PubMed Web of Science ®Google Scholar
• Wang W, Erbe AK, Hank JA, et al. NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7:303–310.
   PubMed Web of Science ®Google Scholar
• Stevenson GT. Three major uncertainties in the antibody therapy of cancer. Haematologica. 2014;99:1538–1546.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42.
   PubMed Web of Science ®Google Scholar
• Romano E, Kusio-Kobialka M, Foukas PG, et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6140–6145.
   Web of Science ®Google Scholar
• Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7:33498–33511.
   Web of Science ®Google Scholar
• Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005;201:779–791.
   PubMed Web of Science ®Google Scholar
• Khanna S, Thomas A, Abate-Daga D, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993–2005.
   PubMed Web of Science ®Google Scholar
• Heery CR, O’Sullivan Coyne GH, Madan R.A, et al. Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J Clin Oncol. 2014;32:5S, abstr. 3064
   Web of Science ®Google Scholar
• Heery CR, O’Sullivan Coyne GH, Marte JL, et al. Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. J Clin Oncol. 2015;33: suppl; abstr 3055.
   Web of Science ®Google Scholar
• Cassler NM, Merrill D, Bichakjian CK, et al. Merkel cell carcinoma therapeutic update. Curr Treat Options Oncol. 2016;17:36.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–1385.
   PubMed Web of Science ®Google Scholar
• Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol. 2016;34:suppl; abstr 5533.
   Google Scholar
• Gulley JL, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol. 2015;33:Abstract 8034.
   Google Scholar
• Verschraegen CF, Chen F, Spigel DR, et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. J Clin Oncol. 2016;34S:abstract 9036.
   Google Scholar
• Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase IB JAVELIN solid tumor trial. Cancer Res. 2016;76:S1–04.
   Web of Science ®Google Scholar
• Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean?. J Exp Med. 2016;213:2835–2840.
   PubMed Web of Science ®Google Scholar
• ASCO Meeting 2016 cited 2016 Nov 25; Available from: http://meetinglibrary.asco.org/abstracts
   Google Scholar
• Verma R, Foster RE, Horgan K, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18:10.
   PubMed Web of Science ®Google Scholar
• Rosental B, Appel MY, Yossef R, et al. The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells. Curr Med Chem. 2012;19:1780–1791.
   PubMed Web of Science ®Google Scholar
• Weintraub K. Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med. 2016;22:8–10.
   PubMed Web of Science ®Google Scholar